中心是国家重点学科、临床重点专科和国家药物临床试验机构认定专业，也是科技部、教育部创新团队和基金委创新群体；包括院士1名、“千人”2名、“万人”领军人才1名、长江学者4名、“杰青”7名、“青千”1名；是中华医学会血液学分会主委和中国医师协会血液学分会会长单位。近5年承担国家重点研发计划，863、973计划，国家科技重大专项等重大课题；获国家科技进步奖等多项奖励及授权专利。团队成员以通讯/第一作者身份在N Engl J Med、J Clin Oncol和Blood等国际顶级期刊上发表一系列改变血液病诊治现状的研究成果；本中心的突出优势：1）建成三个核心公共平台：即“国际先进的血液病精准诊断平台”、和“诊疗技术转化研发平台”以及引领国际的“干细胞移植综合治疗平台”；移植平台诞生了亚洲第一例骨髓移植、创建全球首个非体外去T单倍型移植体系—“北京方案”，采用“北京方案”治疗的病例数量占据世界单倍型移植例数的半壁江山，基本解决供者来源匮乏的世界性难题，迎来“人人都有供者”的新时代。2）规范化诊疗体系支撑重要指南：团队主持/参与60余项国内外多中心临床研究，改变/影响欧美指南/共识28项，主持制定我国指南/共识15项。3）建成覆盖全国25省市协作网络和国内最大干细胞移植样本库。
(1)引领国际的造血干细胞移植诊治综合平台：创建形成国际公认的、首个非体外去T单倍型相合移植体系--“北京方案”，基本解决了供者来源匮乏的世界性难题；建立移植后白血病复发及抗宿主病等的有效防治体系，提供移植后合并症的中国解决方案；建立国际知名的造血干细胞移植培训中心和示范教学基地；(2) 建立了国际先进、国内领先的血液系统疾病精准诊断平台，促进了临床诊断技术的推广和培训；(3) 建立并不断发展国际水平的血液疾病诊治转化研发平台：（4）逐渐成为国际领先、国内先进的血液恶性疾病治疗中心。
National Clinical Research Center for Hematologic Disease
In May 2019, the Ministry of Science and Technology in conjunction with the National Health and Family Planning Commission, CPC Central Military Commission Logistics Support Department and General Administration of Food and Drug Administration officially recognized Peking University People's Hospital as the National Center for Clinical Research of Hematologic Disease. This is the first time that China has set up a national clinical medical research center in the field of hematology. The center is led by Peking University People's Hospital and jointly established by Peking University School of Life Sciences and Peking University Health Science Center to fully utilize the medical resources of the collaborative research network. It is going to create, standardize and promote new technologies for diagnosis and treatment, and carry out original research based on solving clinical problems. It is planned to build a highland that represents China's highest level and leading international standard diagnosis and treatment of hematological disease, and to make a great effort to the promotion of a healthy China strategy.
The major objectives of the center research includes: (1) to maintain the international leading position of hematopoietic stem cell transplantation, through vigorously developing transformation research to form the original key technology, expand transplant indications, further improve the efficacy of transplantation, achieve the popularization of key technologies in China, and change the direction of key diagnostic guidelines in Europe and the United States. (2) Strive to achieve international leadership in the field of blood disease diagnosis; to produce some of the recognized for precise diagnosis of China's independent intellectual property rights of the new biomarkers by translational research; to form the international standard testing system and promotionthrough the international multi-center clinical trial verification. (3) For hematological complicated diseases, to produce new methods of original treatmentby using the translational medicine platform, and through a single-center-multicenter clinical trial verification, and ultimately gradually realize the promotion and influence, change of international important guidelines.
The center is the State key discipline of Ministry of Education, Innovative Group of Ministry of Education and clinical key discipline of Ministry of Health. It is also the Innovative Research Groups of the National Natural Science Foundation of China; including one academician, four persons owned the scholar of the Changjiang River, 7 persons owned the National Science Fund for Distinguished Young Scholars, one person was enrolled in the Thousand Talents Plan, and two people won the honor of excellent talents of Beijing. In the past five years, it has undertaken national key research and development plans, 863, 973 plans, major national science and technology major projects, etc., and won many awards and authorized patents including the second prize of National Science and Technology Progress Award twice, and several other provincial and ministerial scientific awards. Over the past 5 years, more than 500 academic papers have been published, including 400~ SCI papers. The first author of the newsletter published a series of clinical research results in the international top journals such as N Engl J Med, J Clin Oncol and Blood. The Center's outstanding advantages: 1) Three core public platforms were built: "International advanced blood disease precise diagnosis platform", and "translational research and development platform" and the international "stem cell transplantation comprehensive treatment platform". The transplantation platform gave birth to the first bone marrow transplantation in Asia, creating the world's first in vitro T-single The "Beijing Program" of the transplant system, which accounts for half of the world's haplotype transplants, basically solves the worldwide problem of lack of donor sources and usher in a new era of "everyone has a donor." 2) Supporting the important guidelines for standardized diagnosis and treatment system: Hosting/participating more than 60 domestic and international multi-center clinical research, changing/affecting 28 European-American guidelines/consensus, and presiding over 15 guidelines/consensus in China. 3) Established a collaboration network covering 25 provinces and cities nationwide and the largest sample of stem cell transplantation in China.
The important research achievements in recent years include: (1) Leading the international comprehensive platform for the diagnosis and treatment of hematopoietic stem cell transplantation: creating an internationally recognized first in vitro T-haplotype-compatible transplantation system--"Beijing Program", which basically solved the problem. The world's problem of lack of source; establish an effective prevention and treatment system for leukemia recurrence and host disease after transplantation, provide a Chinese solution for post-transplant comorbidities; establish an internationally renowned hematopoietic stem cell transplantation training center and demonstration teaching base; (2) Established an internationally advanced and domestically leading precise diagnosis platform for hematological diseases, and promoted the promotion and training of clinical diagnostic techniques; (3) Established and continuously developed a global level of hematological disease diagnosis and treatment transformation research and development platform: (4) gradually become the international leader, domestic advanced hematological malignant disease treatment center.
Director: Xiaojun Huang
Contact: Meng Lv
Address: No 11 Xizhimen South Street, Beijing 100044, China